tamiflu resistance sparks relenza order, page-8

It gives me comfort seeing GSK actively promote Relenza and seek improvements in delivery and production.

Biota should really be pushing the PR bandwagon, nothing else reflects success as well as a rising share price!

My wish list includes a full nasdaq listing, this would increase analyst coverage and remove the need for active promotion to some degree.

It is now "mid-year"... LANI is due now. Let's keep our fingers crossed... hope for a license deal to a large pharma (not DS).